Flu Drugs Show Promise Against Cognitive Decline, Aging-Related Diseases - poz.com
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
Northwestern University scientists have unearthed a surprising new avenue in the fight against cognitive decline and premature aging, reporting that a class of common flu drugs, including Tamiflu, shows significant promise in people living with HIV. Published in the journal Med, the study reveals that these drugs counteract the degradation of protective sugar molecules, or glycans, thereby reducing inflammation and shielding brain function. This unexpected finding could revolutionize treatment strategies for HIV-associated neurocognitive disorders and broader aging-related conditions like dementia. Despite advancements in antiretroviral treatment, a staggering one-quarter of individuals with HIV still battle debilitating memory and thinking problems, a condition linked to accelerated biological aging. The Northwestern research team, led by Mohamed Abdel-Mohsen, pinpointed chronic inflammation driven by glycan degradation as a key culprit. By analyzing blood samples from over 100 HIV patients and conducting extensive lab and mouse studies, they demonstrated that sialidase inhibitors, typically used to combat influenza, effectively preserve these critical sugar structures. This mechanism suggests a novel therapeutic pathway beyond their traditional antiviral role, addressing a persistent challenge for an aging HIV population. While the findings are compelling, lead author Abdel-Mohsen cautions against immediate self-medication with flu drugs, emphasizing that these preclinical results primarily 'open the door' for further rigorous testing. The next steps involve clinical trials to validate the safety and efficacy of repurposing these existing medications, or developing next-generation versions, specifically for brain and aging-related complications in humans. If successful, this research could unlock a readily available and cost-effective treatment strategy, potentially mitigating the long-term neurological burden on millions globally.